Abstract
Molecular diagnostics (also known as nucleic acid testing) has emerged as a field that promises to renew technological progress in the clinical laboratory and to vastly improve patient care. Although it has been a slower than anticipated adoption in the clinical laboratory setting, molecular diagnostics has begun to overcome the impediments of incomplete genetic knowledge, the development of new technology platforms, and the communication of their use and efficacy to lab personnel and clinicians alike.
A series of technologies developed over the years to address the challenges of molecular diagnostics include eight major areas: amplification technologies (gene and signal), blotting technologies, electrophoretic technologies, microarray technologies, probe technologies, restriction fragment-length polymorphism (RFLP) analysis, RNA inhibition analysis, and single nucleotide polymorphism (SNP) analysis and software. Further, there is significant overlap among these technologies in that they can support one another. These developments have set the stage for excellent growth potential in this marketplace.
Kalorama' s Molecular Diagnostics: Major World Markets completely re-examines the molecular diagnostics market and expands its well respected previous editions. The report features:
- Market Potential in terms of number of tests (testing volume) and market size (dollar volume) through 2016 for strategic planning and new product consideration.
- 110 Tables and Figures detailing the data and trends in each country and segment/subsegment for quick reference and encorporation into proposals, internal memos and business plans.
- In-depth profiles (averaging 5 pages each) of top 10 competitors, detailing product offerings, recent announcements and acquisitions, and strategies..
- Discussion of the major technologies, including developments, products,
benefits and drawbacks of:
- amplification technologies (gene and signal)
- blotting technologies
- electrophoresis technologies
- microarray technologies
- probe technologies
- restriction fragment-length polymorphism (RFLP)
- RNA inhibition analysis
- single nucleotide polymorphism (SNP) analysis
- 14 High level conclusions about the marketplace, each with a discussion of its strategic implication to assist executives in understanding how the trends and data affect their business decisions.
- Two tables (over 70 pages in length) list both marketed products and key "home-brew" molecular tests currently in use.
(The U.S. Market for Molecular Diagnostics) to include all seven of the major world healthcare markets, including:
- France
- Germany
- Italy
- Japan
- Spain
- The United Kingdom
- The United States
Table of Contents
Chapter One: Executive Summary
- Background
- Scope and Methodology
- Size and Growth of Market
- Competitive Picture
- Market Trends and Factors
Chapter Two: Introduction
- Background
- Market Erosion
- Clinical Relevance
- Cost-Benefit Relationships
- Scientific Limitations
- Essential Scientific Foundations
- Genomics
- Genes, Functional Genomics and Disease
- Proteomics
Chapter Three: Molecular Diagnostics Technologies
- Background
- Amplification Technologies
- Gene Amplification
- Signal Amplification
- Probe Technologies
- Microchip Technologies
- Electrophoretic Technologies
- Blotting Technologies
- Single Nucleotide Polymorphism (SNP) Analysis
- Restriction Fragment Length Polymorphism (RFLP) Analysis
- RNA Inhibition (RNAi) Analysis
- Biophotonics
Chapter Four: Applications of Molecular Diagnostics
- The Testing Environment
- Regulatory Issues and Home-Brew Assays
- Molecular Diagnostics Test Distribution and Factors
- Privacy Issues and Legislation
- The Blood Banking Industry
- Commercial Clinical Laboratory Operations
- University/Hospital Laboratory Operations
- Projections
- Blood Banking Analysis
- Genetic Diseases
- Oncology
- Pharmacogenetics
- Infectious Disease Testing
- Chlamydia trachomatis
- Neisseria gonorrhoeae
- Pneumonia
- Human Immunodeficiency Virus (HIV)
- Tuberculosis
- Hepatitis B (HBV)
- Hepatitis C (HCV)
- Human Papillomavirus (HPV)
- Herpes Simplex (HSV)
- West Nile Virus (WNV)
Chapter Five: The Market for Molecular Diagnostics
- Market Size and Trending
- Blood Bank Testing
- Gene and Chromosome Testing
- Oncology Testing
- Pharmacogenetic Testing
- Infectious Disease Testing
- Competitive Picture and Industry Structure
- Future Prospects
Chapter Six: Company Profiles
- Overview
- Abbott Diagnostics (Vysis Division)
- Bayer Diagnostics Division of Bayer Healthcare
- Biotest Diagnostics (Division of Biotest AG)
- Celera Diagnostics (Celera Genomics Group/Applera Corporation)
- Cepheid, Inc.
- Digene Corporation
- Gen-Probe Incorporated
- Innogenetics NV
- Roche Diagnostics Division/Roche Molecular Systems (F. Hoffmann-LaRoche Ltd.)
- Third Wave Technologies
Chapter Seven: Conclusions and Strategic Implications
- First Conclusion
- Implications:
- Second Conclusion
- Implications:
- Third Conclusion
- Implications:
- Fourth Conclusion
- Implications:
- Fifth Conclusion
- Implications:
- Sixth Conclusion
- Implications:
- Seventh Conclusion
- Implications:
- Eighth Conclusion
- Implications:
- Ninth Conclusion
- Implications:
- Tenth Conclusion
- Implications:
- Eleventh Conclusion
- Implications:
- Twelfth Conclusion
- Implications:
- Thirteenth Conclusion
- Implications:
- Fourteenth Conclusion
- Implications:
Appendix: Company Directory
List of Exhibits
Chapter One: Executive Summary
- Table 1-1: Molecular Diagnostics Technologies Description, Advantages, Disadvantages
- Table 1-2: Projected Molecular Diagnostics Market Potential in the Seven Major World Healthcare Markets by Country 2006 - 2016
- Figure 1-1: Trending in the Projected Molecular Diagnostics Market Potential in the Seven Major World Healthcare Markets by Applications Segment (Blood Banking, Cancer, Infectious Disease, Gene/Chromosome Testing, Pharmacogenetics) 2006 - 2016
- Figure 1-2: Trending in the Composition of the Projected Molecular Diagnostics Market Potential in the Seven Major World Healthcare Markets by Applications Segment (Blood Banking, Cancer, Infectious Disease, Gene/Chromosome Testing, Pharmacogenetics) 2006 - 2016
- Table 1-3: Key Active Competitors in the Molecular Diagnostics Products Market by Technologies 2007
Chapter Three: Molecular Diagnostics Technologies
- Table 3-1: Molecular Diagnostics Technologies Description, Advantages, Disadvantages
- Table 3-2: Gene Amplification Technologies
- Table 3-3: Commonly Used Signal Amplification Technologies for Genetic Analysis
Chapter Four: Applications of Molecular Diagnostics
- Table 4-1: Commercially Available Molecular Diagnostics Tests (Company, Analyte, Test Category, Test Name, Technology)
- Table 4-2: Key "Home-Brew" Molecular Diagnostics Assays (Disease/Condition, Specimen Type, Assay Method, Turn-Around Time, Comments)
- Figure 4-1: Distribution of Molecular Diagnostics Testing by Application (Blood Bank, Cancer, Pharmacogenetic, Tissue Typing, Gene/Chromosome, Infectious Disease) 2006
- Table 4-3: Populations of the Seven Major World Healthcare Markets 2006 - 2016
- Table 4-4: Distribution of Populations of the Seven Major World Healthcare Markets: 2006 - 2016
- Table 4-5: Potential Test Volumes for Molecular Diagnostics in the Seven Major World Healthcare Markets by Testing Area (Blood Banking, Gene/Chromosome Disease, Oncology, Pharmacogenetics, Infectious Disease) 2006 - 2016
- Table 4-6: Distribution of Potential Test Volumes for Molecular Diagnostics in the Seven Major World Healthcare Markets by Testing Area (Blood Banking, Gene/Chromosome Disease, Oncology, Pharmacogenetics, Infectious Disease) 2006 - 2016
- Table 4-7: Estimated Blood/Plasma Donation Levels in the Seven Major World Healthcare Markets 2006 - 2016
- Table 4-8: Potential Levels of Molecular Testing in Blood Banking in the Seven Major World Healthcare Markets 2006 - 2016
- Table 4-9: Commercially Available Molecular (Nucleic Acid) Tests for Blood, Plasma and Organ Donor Screening in the United States (Trade Name, Format, Sample, Use, Manufacturer, Approval Date) 2006
- Table 4-10: Potential Levels of Molecular Testing in Blood Banking in France by Category (HIV, HCV, HBV, HAV, HTLV, WNV, Others) 2006 - 2016
- Table 4-11: Potential Levels of Molecular Testing in Blood Banking in Germany by Category (HIV, HCV, HBV, HAV, HTLV, WNV, Others) 2006 - 2016
- Table 4-12: Potential Levels of Molecular Testing in Blood Banking in Italy by Category (HIV, HCV, HBV, HAV, HTLV, WNV, Others) 2006 - 2016
- Table 4-13: Potential Levels of Molecular Testing in Blood Banking in Japan by Category (HIV, HCV, HBV, HAV, HTLV, WNV, Others) 2006 - 2016
- Table 4-14: Potential Levels of Molecular Testing in Blood Banking in Spain by Category (HIV, HCV, HBV, HAV, HTLV, WNV, Others) 2006 - 2016
- Table 4-15: Potential Levels of Molecular Testing in Blood Banking in the United Kingdom by Category (HIV, HCV, HBV, HAV, HTLV, WNV, Others) 2006 - 2016
- Table 4-14: Potential Levels of Molecular Testing in Blood Banking in the United States by Category (HIV, HCV, HBV, HAV, HTLV, WNV, Others) 2006 - 2016
- Table 4-17: Key Hereditary Diseases (Condition, Incidence, and Inheritance/Cause)
- Table 4-18: Potential Levels of Molecular Testing in Genetic Analysis in the Seven Major World Healthcare Markets by Category (Heterozygote, Presymptomatic, Prenatal, Newborn Screening) 2006 - 2016
- Table 4-19: Potential Levels of Molecular Testing in Genetic Analysis in the Seven Major World Healthcare Markets by Country 2006 - 2016
- Table 4-20: Potential Levels of Molecular Testing in Oncology in the Seven Major World Healthcare Markets by Category (Management vs Susceptibility) 2006 - 2016
- Table 4-21: Potential Levels of Molecular Testing in Oncology in the Seven Major World Healthcare Markets by Country 2006 - 2016
- Table 4-22: Drugs Affected by the Cytochrome p450 System
- Table 4-23: Potential Levels of Molecular Testing in Pharmacogenetics in the Seven Major World Healthcare Markets by Category (HIV/AIDS, Neuropharmacology, Immune Disease, Cancer, Other) 2006 - 2016
- Table 4-24: Potential Levels of Molecular Testing in Pharmacogenetics in the Seven Major World Healthcare Markets by Country 2006 - 2016
- Table 4-25: Potential Levels of Molecular Testing in Infectious Disease in the Seven Major World Healthcare Markets by Category (CT, NG, Pneumonia, HIV, HBV, HCV, HPV, MT, HSV) 2006 - 2016
- Table 4-26: Potential Levels of Molecular Testing in Infectious Disease in the Seven Major World Healthcare Markets by Country 2006 - 2016
Chapter Five: The Market for Molecular Diagnostics
- Table 5-1: Projected Molecular Diagnostics Market Potential in the Seven Major World Healthcare Markets by Country 2006 - 2016
- Table 5-2: Potential Market for Molecular Diagnostics Testing in France by Testing Area (Blood Banking, Gene/Chromosome Disease, Oncology, Pharmacogenetics, Infectious Disease) 2006 - 2016
- Table 5-3: Potential Market for Molecular Diagnostics Testing in Germany by Testing Area (Blood Banking, Gene/Chromosome Disease, Oncology, Pharmacogenetics, Infectious Disease) 2006 - 2016
- Table 5-4: Potential Market for Molecular Diagnostics Testing in Italy by Testing Area (Blood Banking, Gene/Chromosome Disease, Oncology, Pharmacogenetics, Infectious Disease) 2006 - 2016
- Table 5-5: Potential Market for Molecular Diagnostics Testing in Japan by Testing Area (Blood Banking, Gene/Chromosome Disease, Oncology, Pharmacogenetics, Infectious Disease) 2006 - 2016
- Table 5-6: Potential Market for Molecular Diagnostics Testing in Spain by Testing Area (Blood Banking, Gene/Chromosome Disease, Oncology, Pharmacogenetics, Infectious Disease) 2006 - 2016
- Table 5-7: Potential Market for Molecular Diagnostics Testing in the United Kingdom by Testing Area (Blood Banking, Gene/Chromosome Disease, Oncology, Pharmacogenetics, Infectious Disease) 2006 - 2016
- Table 5-8: Potential Market for Molecular Diagnostics Testing in the United States by Testing Area (Blood Banking, Gene/Chromosome Disease, Oncology, Pharmacogenetics, Infectious Disease) 2006 - 2016
- Figure 5-1: Trending in the Potential Markets for Molecular Diagnostics in the Seven Major World Healthcare Markets 2006 - 2016
- Figure 5-2: Trending in the Composition of Potential Markets for Molecular Diagnostics in the Seven Major World Healthcare Markets 2006 - 2016
- Table 5-9: Table 5-8 Potential Market for Molecular Diagnostics Testing in the Seven Major World Healthcare Markets by Testing Area (Blood Banking, Gene/ Chromosome Disease, Oncology, Pharmacogenetics, Infectious Disease) 2006 - 2016
- Figure 5-3: Trending in the Potential Test Volume for Molecular Diagnostics in the Seven Major World Healthcare Markets by Testing Area (Blood Banking, Gene/Chromosome Disease, Oncology, Pharmacogenetics, Infectious Disease) 2006 - 2016
- Figure 5-4: Trending in the Composition of Potential Test Volume for Molecular Diagnostics in the Seven Major World Healthcare Markets by Testing Area (Blood Banking, Gene/Chromosome Disease, Oncology, Pharmacogenetics, Infectious Disease) 2006 - 2016
- Table 5-10: Projected Blood Banking and Plasmapheresis Molecular Diagnostics Testing Market Potential in the Seven Major World Healthcare Markets by Country 2006 - 2016
- Figure 5-5: Trending in the Projected Blood Banking and Plasmapheresis Molecular Diagnostics Testing Market Potential in the Seven Major World Healthcare Markets 2006 - 2016
- Figure 5-6: Trending in the Projected Blood Banking and Plasmapheresis Molecular Diagnostics Potential Testing Volume in the Seven Major World Healthcare Markets 2006 - 2016
- Table 5-11: Projected Blood Banking and Plasmapheresis Molecular Diagnostics Testing Volume Potential in the Seven Major World Healthcare Markets by Test Type (HIV, HCV, HBV, HAV, HTLV, WNV, Others) 2006 - 2016
- Figure 5-7: Trending in the Composition of the Projected Blood Banking and Plasmapheresis Molecular Diagnostics Testing Volume Potential in the Seven Major World Healthcare Markets 2006 - 2016
- Table 5-12: Projected Blood Banking and Plasmapheresis Molecular Diagnostics Testing Volume Potential in France by Test Type (HIV, HCV, HBV, HAV, HTLV, WNV, Others) 2006 - 2016
- Table 5-13: Projected Blood Banking and Plasmapheresis Molecular Diagnostics Testing Volume Potential in Germany by Test Type (HIV, HCV, HBV, HAV, HTLV, WNV, Others) 2006 - 2016
- Table 5-14: Projected Blood Banking and Plasmapheresis Molecular Diagnostics Testing Volume Potential in Italy by Test Type (HIV, HCV, HBV, HAV, HTLV, WNV, Others) 2006 - 2016
- Table 5-15: Projected Blood Banking and Plasmapheresis Molecular Diagnostics Testing Volume Potential in Japan by Test Type (HIV, HCV, HBV, HAV, HTLV, WNV, Others) 2006 - 2016
- Table 5-16: Projected Blood Banking and Plasmapheresis Molecular Diagnostics Testing Volume Potential in Spain by Test Type (HIV, HCV, HBV, HAV, HTLV, WNV, Others) 2006 - 2016
- Table 5-17: Projected Blood Banking and Plasmapheresis Molecular Diagnostics Testing Volume Potential in the United Kingdom by Test Type (HIV, HCV, HBV, HAV, HTLV, WNV, Others) 2006 - 2016
- Table 5-18: Projected Blood Banking and Plasmapheresis Molecular Diagnostics Testing Volume Potential in the United States by Test Type (HIV, HCV, HBV, HAV, HTLV, WNV, Others) 2006 - 2016
- Table 5-19: Projected Genetic and Chromosome Molecular Diagnostics Testing Market Potential in the Seven Major World Healthcare Markets by Country 2006- 2016
- Figure 5-8: Trending in the Projected Genetic and Chromosome Molecular Diagnostics Testing Market Potential in the Seven Major World Healthcare Markets 2006 - 2016
- Figure 5-9: Trending in the Projected Genetic and Chromosome Molecular Diagnostics Testing Market Assay Volume Potential in the Seven Major World Healthcare Markets 2006 - 2016
- Table 5-20: Projected Genetic and Chromosome Molecular Diagnostics Testing Volume Potential in the Seven Major World Healthcare Markets by Application (Heterozygote Testing, Presymptomatic Disease Testing, Prenatal Testing, Newborn Testing) 2006 - 2016
- Figure 5-10: Trending in the Composition of the Projected Genetic and Chromosome Molecular Diagnostics Testing Volume Potential in the Seven Major World Healthcare Markets 2006 - 2016
- Table 5-21: Projected Genetic and Chromosome Molecular Diagnostics Testing Volume Potential in France by Application (Heterozygote Testing, Presymptomatic Disease Testing, Prenatal Testing, Newborn Testing) 2006 - 2016
- Table 5-22: Projected Genetic and Chromosome Molecular Diagnostics Testing Volume Potential in Germany by Application (Heterozygote Testing, Presymptomatic Disease Testing, Prenatal Testing, Newborn Testing) 2006 - 2016
- Table 5-23: Projected Genetic and Chromosome Molecular Diagnostics Testing Volume Potential in Italy by Application (Heterozygote Testing, Presymptomatic Disease Testing, Prenatal Testing, Newborn Testing) 2006 - 2016
- Table 5-24: Projected Genetic and Chromosome Molecular Diagnostics Testing Volume Potential in Japan by Application (Heterozygote Testing, Presymptomatic Disease Testing, Prenatal Testing, Newborn Testing) 2006 - 2016
- Table 5-25: Projected Genetic and Chromosome Molecular Diagnostics Testing Volume Potential in Spain by Application (Heterozygote Testing, Presymptomatic Disease Testing, Prenatal Testing, Newborn Testing) 2006 - 2016
- Table 5-26: Projected Genetic and Chromosome Molecular Diagnostics Testing Volume Potential in the United Kingdom by Application (Heterozygote Testing, Presymptomatic Disease Testing, Prenatal Testing, Newborn Testing) 2006 - 2016
- Table 5-27: Projected Genetic and Chromosome Molecular Diagnostics Testing Volume Potential in the United States by Application (Heterozygote Testing, Presymptomatic Disease Testing, Prenatal Testing, Newborn Testing) 2006 - 2016
- Table 5-28: Projected Oncology Molecular Diagnostics Testing Market Potential in the Seven Major World Healthcare Markets by Country 2006- 2016
- Figure 5-11: Trending in the Projected Oncology Molecular Diagnostics Testing Market Potential in the Seven Major World Healthcare Markets 2006 - 2016
- Figure 5-12: Trending in the Projected Oncology Molecular Diagnostics Testing Market Assay Volume Potential in the Seven Major World Healthcare Markets 2006 - 2016
- Table 5-29: Projected Molecular Oncology Diagnostics Testing Volume Potential in the Seven Major World Healthcare Markets by Application (Cancer Management vs Cancer Susceptibility) 2006 - 2016
- Figure 5-13: Trending in the Composition of the Projected Oncology Molecular Diagnostics Testing Market Assay Volume Potential in the Seven Major World Healthcare Markets: 2006 - 2016
- Table 5-30: Projected Molecular Oncology Diagnostics Testing Volume Potential in France by Application (Cancer Management vs Cancer Susceptibility) 2006 - 2016
- Table 5-31: Projected Molecular Oncology Diagnostics Testing Volume Potential in Germany by Application (Cancer Management vs Cancer Susceptibility) 2006 - 2016
- Table 5-32: Projected Molecular Oncology Diagnostics Testing Volume Potential in Italy by Application (Cancer Management vs Cancer Susceptibility) 2006 - 2016
- Table 5-33: Projected Molecular Oncology Diagnostics Testing Volume Potential in Japan by Application (Cancer Management vs Cancer Susceptibility) 2006 - 2016
- Table 5-34: Projected Molecular Oncology Diagnostics Testing Volume Potential in Spain by Application (Cancer Management vs Cancer Susceptibility) 2006 - 2016
- Table 5-35: Projected Molecular Oncology Diagnostics Testing Volume Potential in the United Kingdom by Application (Cancer Management vs Cancer Susceptibility) 2006 - 2016
- Table 5-36: Projected Molecular Oncology Diagnostics Testing Volume Potential in the United States by Application (Cancer Management vs Cancer Susceptibility) 2006 - 2016
- Table 5-37: Projected Pharmacogenetic Molecular Diagnostics Testing Market Potential in the Seven Major World Healthcare Markets by Country 2006 - 2016
- Figure 5-14: Trending in the Projected Pharmacogenetic Molecular Diagnostics Testing Market Potential in the Seven Major World Healthcare Markets 2006 - 2016
- Table 5-38: Projected Molecular Pharmacogenetics Testing Volume Potential in the Seven Major World Healthcare Markets by Application (HIV/AIDS Testing, Neuropharmaceutical Testing, Immune Therapeutics Testing, Cancer Testing, Other) 2006 - 2016
- Figure 5-15: Trending in the Projected Pharmacogenetics Molecular Diagnostics Testing Market Assay Volume Potential in the Seven Major World Healthcare Markets: 2006 - 2016
- Figure 5-16: Trending in the Composition of the Projected Pharmacogenetics Molecular Diagnostics Testing Market Assay Volume Potential in the Seven Major World Healthcare Markets: 2006 - 2016
- Table 5-39: Potential Pharmacogenetic Molecular Diagnostics Testing Volume in France by Application (HIV/AIDS Testing, Neuropharmaceutical Testing, Immune Therapeutics Testing, Cancer Testing, Other) 2006 - 2016
- Table 5-40: Potential Pharmacogenetic Molecular Diagnostics Testing Volume in Germany by Application (HIV/AIDS Testing, Neuropharmaceutical Testing, Immune Therapeutics Testing, Cancer Testing, Other) 2006 - 2016
- Table 5-41: Potential Pharmacogenetic Molecular Diagnostics Testing Volume in Italy by Application (HIV/AIDS Testing, Neuropharmaceutical Testing, Immune Therapeutics Testing, Cancer Testing, Other) 2006 - 2016
- Table 5-42: Potential Pharmacogenetic Molecular Diagnostics Testing Volume in Japan by Application (HIV/AIDS Testing, Neuropharmaceutical Testing, Immune Therapeutics Testing, Cancer Testing, Other) 2006 - 2016
- Table 5-43: Potential Pharmacogenetic Molecular Diagnostics Testing Volume in Spain by Application (HIV/AIDS Testing, Neuropharmaceutical Testing, Immune Therapeutics Testing, Cancer Testing, Other) 2006 - 2016
- Table 5-44: Potential Pharmacogenetic Molecular Diagnostics Testing Volume in the United Kingdom by Application (HIV/AIDS Testing, Neuropharmaceutical Testing, Immune Therapeutics Testing, Cancer Testing, Other) 2006 - 2016
- Table 5-45: Potential Pharmacogenetic Molecular Diagnostics Testing Volume in the United States by Application (HIV/AIDS Testing, Neuropharmaceutical Testing, Immune Therapeutics Testing, Cancer Testing, Other) 2006 - 2016
- Table 5-46: Projected Molecular Diagnostics Infectious Disease Testing Market Potential in the Seven Major World Healthcare Markets by Country 2006 - 2016
- Figure 5-17: Trending in the Projected Infectious Disease Molecular Diagnostics Testing Market Potential in the Seven Major World Healthcare Markets: 2006 - 2016
- Figure 5-18: Trending in the Projected Infectious Disease Molecular Diagnostics Testing Market Assay Volume Potential in the Seven Major World Healthcare Markets: 2006 - 2016
- Figure 5-19: Trending in the Composition of the Projected Infectious Disease Molecular Diagnostics Testing Market Assay Volume Potential in the Seven Major World Healthcare Markets: 2006 - 2016
- Figure 5-20: Trending in the Projected Test Volume for Molecular Diagnostics in Infectious Disease Testing in the Seven Major World Healthcare Markets by Application: 2006 - 2016
- Table 5-47: Projected Molecular Diagnostics Infectious Disease Testing Volume Potential in the Seven Major World Healthcare Markets by Application (CT, NG, Pneumonia, HIV, HBV, HCV, HPV, MT, HSV) 2006 - 2016
- Table 5-48: Projected Infectious Disease Molecular Diagnostics Potential Testing Volume in France by Application (CT, NG, Pneumonia, HIV, HBV, HCV, HPV, MT, HSV) 2006 - 2016
- Table 5-49: Projected Infectious Disease Molecular Diagnostics Potential Testing Volume in Germany by Application (CT, NG, Pneumonia, HIV, HBV, HCV, HPV, MT, HSV) 2006 - 2016
- Table 5-50: Projected Infectious Disease Molecular Diagnostics Potential Testing Volume in Italy by Application (CT, NG, Pneumonia, HIV, HBV, HCV, HPV, MT, HSV) 2006 - 2016
- Table 5-51: Projected Infectious Disease Molecular Diagnostics Potential Testing Volume in Japan by Application (CT, NG, Pneumonia, HIV, HBV, HCV, HPV, MT, HSV) 2006 - 2016
- Table 5-52: Projected Infectious Disease Molecular Diagnostics Potential Testing Volume in Spain by Application (CT, NG, Pneumonia, HIV, HBV, HCV, HPV, MT, HSV) 2006 - 2016
- Table 5-53: Projected Infectious Disease Molecular Diagnostics Potential Testing Volume in the United Kingdom by Application (CT, NG, Pneumonia, HIV, HBV, HCV, HPV, MT, HSV) 2006 - 2016
- Table 5-54: Projected Infectious Disease Molecular Diagnostics Potential Testing Volume in the United States by Application (CT, NG, Pneumonia, HIV, HBV, HCV, HPV, MT, HSV) 2006 - 2016
- Table 5-55: Key Active Competitors in the Molecular Diagnostics Products Market by Technologies 2007
